{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:20:11Z","timestamp":1773026411064,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00393-024-01536-5","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T06:01:50Z","timestamp":1721455310000},"page":"455-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["FAPI-PET\/CT zur Quantifizierung der Gewebeantwort bei rheumatischen Erkrankungen","FAPI-PET-CT for quantification of the tissue response in rheumatic diseases"],"prefix":"10.1007","volume":"83","author":[{"given":"Yuriko","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea-Hermina","family":"Gy\u00f6rfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Merkt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Distler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"issue":"5","key":"1536_CR1","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.3892\/mmr.2015.3197","volume":"11","author":"F Zi","year":"2015","unstructured":"Zi\u00a0F, He\u00a0J, He\u00a0D, Li\u00a0Y, Yang\u00a0L, Cai\u00a0Z (2015) Fibroblast activation protein alpha in tumor microenvironment: recent progression and implications (review). Mol Med Rep 11(5):3203\u20133211","journal-title":"Mol Med Rep"},{"issue":"9","key":"1536_CR2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner\u00a0T, Loktev\u00a0A, Altmann\u00a0A, Giesel\u00a0F, Kratochwil\u00a0C, Debus\u00a0J et\u00a0al (2018) Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J\u00a0Nucl Med 59(9):1415\u20131422","journal-title":"J Nucl Med"},{"issue":"1","key":"1536_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jcmm.14745","volume":"24","author":"Y An","year":"2020","unstructured":"An\u00a0Y, Liu\u00a0F, Chen\u00a0Y, Yang\u00a0Q (2020) Crosstalk between cancer-associated fibroblasts and immune cells in cancer. J\u00a0Cell Mol Med 24(1):13\u201324","journal-title":"J Cell Mol Med"},{"issue":"3","key":"1536_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald\u00a0AA, Weiner\u00a0LM (2020) The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev 39(3):783\u2013803","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"1536_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cpet.2023.02.007","volume":"18","author":"Y Mori","year":"2023","unstructured":"Mori\u00a0Y, Kratochwil\u00a0C, Haberkorn\u00a0U, Giesel\u00a0FL (2023) Fibroblast activation protein inhibitor theranostics: early clinical translation. PET Clin 18(3):419\u2013428","journal-title":"PET Clin"},{"issue":"3","key":"1536_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel\u00a0FL, Kratochwil\u00a0C, Lindner\u00a0T, Marschalek\u00a0MM, Loktev\u00a0A, Lehnert\u00a0W et\u00a0al (2019) (68)Ga-FAPI PET\/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J\u00a0Nucl Med 60(3):386\u2013392","journal-title":"J Nucl Med"},{"key":"1536_CR7","doi-asserted-by":"crossref","unstructured":"Guglielmo P, Alongi P, Baratto L, Abenavoli E, Buschiazzo A, Celesti G et\u00a0al (2023) Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A\u00a0Systematic Review of the Literature. Life 13(9)","DOI":"10.3390\/life13091821"},{"issue":"11","key":"1536_CR8","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.2967\/jnumed.123.266046","volume":"64","author":"SA Koerber","year":"2023","unstructured":"Koerber\u00a0SA, Rohrich\u00a0M, Walkenbach\u00a0L, Liermann\u00a0J, Choyke\u00a0PL, Fink\u00a0C et\u00a0al (2023) Impact of (68)Ga-FAPI PET\/CT on staging and oncologic management in a\u00a0cohort of 226 patients with various cancers. J\u00a0Nucl Med 64(11):1712\u20131720","journal-title":"J Nucl Med"},{"issue":"6","key":"1536_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil\u00a0C, Flechsig\u00a0P, Lindner\u00a0T, Abderrahim\u00a0L, Altmann\u00a0A, Mier\u00a0W et\u00a0al (2019) (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J\u00a0Nucl Med 60(6):801\u2013805","journal-title":"J Nucl Med"},{"issue":"8","key":"1536_CR10","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00259-019-04346-z","volume":"46","author":"FL Giesel","year":"2019","unstructured":"Giesel\u00a0FL, Heussel\u00a0CP, Lindner\u00a0T, Rohrich\u00a0M, Rathke\u00a0H, Kauczor\u00a0HU et\u00a0al (2019) FAPI-PET\/CT improves staging in a\u00a0lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging 46(8):1754\u20131755","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1536_CR11","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","volume":"48","author":"K Dendl","year":"2021","unstructured":"Dendl\u00a0K, Koerber\u00a0SA, Finck\u00a0R, Mokoala\u00a0KMG, Staudinger\u00a0F, Schillings\u00a0L et\u00a0al (2021) (68)Ga-FAPI-PET\/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging 48(12):4089\u20134100","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1536_CR12","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","volume":"3","author":"C Bergmann","year":"2021","unstructured":"Bergmann\u00a0C, Distler\u00a0JHW, Treutlein\u00a0C, Tascilar\u00a0K, Muller\u00a0AT, Atzinger\u00a0A et\u00a0al (2021) (68)Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a\u00a0single-centre, pilot study. Lancet Rheumatol 3(3):e185\u2013e194","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"1536_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt\u00a0W, Freitag\u00a0M, Claus\u00a0M, Kolb\u00a0P, Falcone\u00a0V, Rohrich\u00a0M et\u00a0al (2024) Third-generation CD19.CAR-T\u00a0cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 83(4):543\u2013546","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1536_CR14","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00259-022-06081-4","volume":"50","author":"C Treutlein","year":"2023","unstructured":"Treutlein\u00a0C, Distler\u00a0JHW, Tascilar\u00a0K, Fakhouri\u00a0SC, Gyorfi\u00a0AH, Atzinger\u00a0A et\u00a0al (2023) Assessment of myocardial fibrosis in patients with systemic sclerosis using [(68)Ga]Ga-FAPI-04-PET-CT. Eur J Nucl Med Mol Imaging 50(6):1629\u20131635","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1536_CR15","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/annrheumdis-2020-217408","volume":"79","author":"C Schmidkonz","year":"2020","unstructured":"Schmidkonz\u00a0C, Rauber\u00a0S, Atzinger\u00a0A, Agarwal\u00a0R, Gotz\u00a0TI, Soare\u00a0A et\u00a0al (2020) Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis 79(11):1485\u20131491","journal-title":"Ann Rheum Dis"},{"key":"1536_CR16","volume-title":"Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission","author":"M Rohrich","year":"2024","unstructured":"Rohrich\u00a0M, Rosales\u00a0JJ, Hoppner\u00a0J, Kvacskay\u00a0P, Blank\u00a0N, Loi\u00a0L et\u00a0al (2024) Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission. Rheumatology, Oxford"},{"key":"1536_CR17","doi-asserted-by":"crossref","unstructured":"Rauber S, Mohammadian H, Schmidkonz C, Atzinger A, Soare A, Treutlein C et\u00a0al (2024) CD200(+) fibroblasts form a\u00a0pro-resolving mesenchymal network in arthritis. Nat Immunol","DOI":"10.1038\/s41590-024-01774-4"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01536-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:06:16Z","timestamp":1723561576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01536-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01536-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"4 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Distler weist auf folgende Beziehungen hin: Beratert\u00e4tigkeit f\u00fcr AbbVie, Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, Genentech, GSK, Inventiva, Janssen, Novartis, Pfizer, Roche und UCB; Erhalt von Forschungsunterst\u00fctzung durch AbbVie, Anamar, Argenx, ARXX, BMS, Bayer Pharma, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, ExoTherapeutics, Galapagos, GSK, Inventiva, Kiniksa, Lassen, Novartis, Sanofi-Aventis, RedX, UCB; Aktieninhaber von 4D Science und Scientific Lead of FibroCure. Y.\u00a0Mori, F.L.\u00a0Giesel, A.-H.\u00a0Gy\u00f6rfi und W.\u00a0Merkt geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}